Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Neuphoria Therapeutics (NASDAQ:NEUP) from a sell rating to a hold rating in a research note released on Saturday.

NEUP has been the topic of a number of other reports. Maxim Group boosted their price objective on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Neuphoria Therapeutics in a research note on Tuesday, August 26th. Finally, Weiss Ratings cut shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.00.

Neuphoria Therapeutics Trading Down 1.9%

Shares of Neuphoria Therapeutics stock opened at $4.70 on Friday. The stock has a 50-day moving average price of $10.43 and a 200 day moving average price of $8.47. The company has a market cap of $11.09 million, a P/E ratio of -0.96 and a beta of 0.51. Neuphoria Therapeutics has a 1 year low of $2.77 and a 1 year high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its earnings results on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, equities analysts forecast that Neuphoria Therapeutics will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Neuphoria Therapeutics

In other Neuphoria Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 639,110 shares of the business’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $5.14 per share, for a total transaction of $3,285,025.40. Following the acquisition, the insider owned 875,328 shares of the company’s stock, valued at $4,499,185.92. This trade represents a 270.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Persistent Asset Partners Ltd bought a new stake in shares of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,908 shares of the company’s stock, valued at approximately $58,000. Persistent Asset Partners Ltd owned approximately 0.21% of Neuphoria Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.